BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 11486703)

  • 1. Economic analysis of granulocyte colony stimulating factor as adjunct therapy for older patients with acute myelogenous leukemia (AML): estimates from a Southwest Oncology Group clinical trial.
    Bennett CL; Hynes D; Godwin J; Stinson TJ; Golub RM; Appelbaum FR;
    Cancer Invest; 2001; 19(6):603-10. PubMed ID: 11486703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031).
    Godwin JE; Kopecky KJ; Head DR; Willman CL; Leith CP; Hynes HE; Balcerzak SP; Appelbaum FR
    Blood; 1998 May; 91(10):3607-15. PubMed ID: 9572995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost analyses of adjunct colony stimulating factors for acute leukemia: can they improve clinical decision making.
    Bennett CL; Stinson TJ; Laver JH; Bishop MR; Godwin JE; Tallman MS
    Leuk Lymphoma; 2000 Mar; 37(1-2):65-70. PubMed ID: 10721770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost analyses of adjunct colony stimulating factors for older patients with acute myeloid leukaemia : can they improve clinical decision making?
    Bennett CL; Schumock GT
    Drugs Aging; 2003; 20(7):479-83. PubMed ID: 12749746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B.
    Stone RM; Berg DT; George SL; Dodge RK; Paciucci PA; Schulman P; Lee EJ; Moore JO; Powell BL; Schiffer CA
    N Engl J Med; 1995 Jun; 332(25):1671-7. PubMed ID: 7760868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor.
    Estey E; Thall P; Andreeff M; Beran M; Kantarjian H; O'Brien S; Escudier S; Robertson LE; Koller C; Kornblau S
    J Clin Oncol; 1994 Apr; 12(4):671-8. PubMed ID: 7512125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of granulocyte colony-stimulating factor use during induction for acute myelogenous leukemia in children: a report from the Children's Cancer Group.
    Alonzo TA; Kobrinsky NL; Aledo A; Lange BJ; Buxton AB; Woods WG
    J Pediatr Hematol Oncol; 2002 Nov; 24(8):627-35. PubMed ID: 12439034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Granulocyte colony-stimulating factor following chemotherapy in elderly patients with newly diagnosed acute myelogenous leukemia.
    Maslak PG; Weiss MA; Berman E; Yao TJ; Tyson D; Golde DW; Scheinberg DA
    Leukemia; 1996 Jan; 10(1):32-9. PubMed ID: 8558934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and conduct of a double-blind, placebo-controlled trial of daunorubicin and cytarabine with or without granulocyte colony-stimulating factor in elderly patients with acute myeloid leukemia: a Southwest Oncology Group study.
    Godwin J
    J Natl Cancer Inst Monogr; 1995; (19):31-5. PubMed ID: 7577202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia.
    Löwenberg B; van Putten W; Theobald M; Gmür J; Verdonck L; Sonneveld P; Fey M; Schouten H; de Greef G; Ferrant A; Kovacsovics T; Gratwohl A; Daenen S; Huijgens P; Boogaerts M; ;
    N Engl J Med; 2003 Aug; 349(8):743-52. PubMed ID: 12930926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination chemotherapy with G-CSF, M-CSF and EPO: successful treatment for acute myelogenous leukemia without blood transfusion at lower medical costs.
    Kaito K; Kobayashi M; Sakamoto M; Shimada T; Masuoka H; Nishiwaki K; Saeki A; Sekita T; Otsubo H; Hosoya T
    Acta Haematol; 1998; 100(1):57-60. PubMed ID: 9691149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors.
    Mayordomo JI; Rivera F; Díaz-Puente MT; Lianes P; Colomer R; López-Brea M; López E; Paz-Ares L; Hitt R; García-Ribas I
    J Natl Cancer Inst; 1995 Jun; 87(11):803-8. PubMed ID: 7540696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact on acute myeloid leukemia relapse in granulocyte colony-stimulating factor application: a meta-analysis.
    Feng X; Lan H; Ruan Y; Li C
    Hematology; 2018 Oct; 23(9):581-589. PubMed ID: 29516766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.
    Creutzig U; Zimmermann M; Lehrnbecher T; Graf N; Hermann J; Niemeyer CM; Reiter A; Ritter J; Dworzak M; Stary J; Reinhardt D
    J Clin Oncol; 2006 Sep; 24(27):4499-506. PubMed ID: 16983120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
    Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost of de novo acute myeloid leukemia induction therapy in adults: analysis of EORTC-GIMEMA AML10 and FLANG regimens.
    Clavio M; Quintino S; Masoudi B; Carrara S; Cerri R; Pierri I; Canepa L; Miglino M; Muner P; Damasio E; Gobbi M
    J Exp Clin Cancer Res; 2001 Jun; 20(2):165-73. PubMed ID: 11484970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of previously untreated elderly patients with AML: a propensity score-matched comparison of clofarabine vs. FLAG.
    Scappaticci GB; Marini BL; Nachar VR; Uebel JR; Vulaj V; Crouch A; Bixby DL; Talpaz M; Perissinotti AJ
    Ann Hematol; 2018 Apr; 97(4):573-584. PubMed ID: 29288428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM).
    Witz F; Sadoun A; Perrin MC; Berthou C; Brière J; Cahn JY; Lioure B; Witz B; François S; Desablens B; Pignon B; Le Prisé PY; Audhuy B; Caillot D; Casassus P; Delain M; Christian B; Tellier Z; Polin V; Hurteloup P; Harousseau JL
    Blood; 1998 Apr; 91(8):2722-30. PubMed ID: 9531581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group.
    Dombret H; Chastang C; Fenaux P; Reiffers J; Bordessoule D; Bouabdallah R; Mandelli F; Ferrant A; Auzanneau G; Tilly H
    N Engl J Med; 1995 Jun; 332(25):1678-83. PubMed ID: 7539109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia.
    Pui CH; Boyett JM; Hughes WT; Rivera GK; Hancock ML; Sandlund JT; Synold T; Relling MV; Ribeiro RC; Crist WM; Evans WE
    N Engl J Med; 1997 Jun; 336(25):1781-7. PubMed ID: 9187068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.